Alaunos Therapeutics (TCRT) Accumulated Expenses (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Accumulated Expenses data on file, last reported at $195000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 15.58% year-over-year to $195000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195000.0 (down 15.58% YoY) and the FY2025 annual result came in at $200000.0, up 13.64% from the prior year.
• Accumulated Expenses slipped to $195000.0 in Q1 2026, from $200000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.7 million in Q3 2022 to a low of $78000.0 in Q3 2025.
• A 5-year average of $2.3 million and a median of $568000.0 in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 881.83% — and 2023, when it tumbled 89.59%.
• Tracing TCRT's Accumulated Expenses over 5 years: stood at $5.5 million in 2022, then plunged by 89.59% to $568000.0 in 2023, then sank by 69.01% to $176000.0 in 2024, then advanced by 13.64% to $200000.0 in 2025, then retreated by 2.5% to $195000.0 in 2026.
• The last three Accumulated Expenses figures came in at $195000.0 (Q1 2026), $200000.0 (Q4 2025), and $78000.0 (Q3 2025), per Business Quant data.